Asterias Biotherapeutics, Inc., a Subsidiary of BioTime (BTX), Acquires Geron Corporation (GERN)’s Embryonic Stem Cell Assets
10/1/2013 10:51:31 AM
MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--Asterias Biotherapeutics, Inc. and BioTime, Inc. (NYSE MKT: BTX) jointly announced today the closing of the transactions under the Asset Contribution Agreement (the “Agreement”) with Geron Corporation, previously announced on January 7, 2013, pursuant to which Asterias Biotherapeutics acquired Geron’s human embryonic stem (hES) cell assets, as well as rights to use certain human embryonic stem cell lines, minority stakes in two of BioTime's subsidiaries and stock from BioTime.
Help employers find you! Check out all the jobs and post your resume.
comments powered by